Skip to main content
Jinyu Bio-Technology Co.,Ltd. logo

Jinyu Bio-Technology Co.,Ltd. — Investor Relations & Filings

Ticker · 600201 ISIN · CNE000000Y37 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,776 across all filing types
Latest filing 2023-04-20 Regulatory Filings
Country CN China
Listing Shanghai Stock Exchange 600201

About Jinyu Bio-Technology Co.,Ltd.

http://jinyubiotech.com/

Jinyu Bio-Technology Co., Ltd. focuses on the research, development, and manufacturing of veterinary biological products and pharmaceuticals. The company is a prominent supplier of animal vaccines, particularly specializing in Foot-and-Mouth Disease (FMD) vaccines, brucellosis vaccines, and solutions for swine and poultry diseases. It utilizes advanced biotechnology platforms, including large-scale suspension culture and high-efficiency purification processes, to produce high-titer, high-purity biologicals. The organization operates sophisticated research facilities and Biosafety Level 3 (P3) laboratories to support the development of diagnostic reagents and preventive treatments. Its operations center on enhancing animal health through scientific innovation, providing comprehensive disease control strategies for the global livestock industry and large-scale agricultural operations.

Recent filings

Filing Released Lang Actions
金宇生物技术股份有限公司关于2022年度计提资产减值准备的公告
Regulatory Filings Classification · 95% confidence The document is an announcement by the company regarding the asset impairment provision for the fiscal year 2022. It details the amounts of impairment losses recognized, the accounting standards applied, and the impact on the company's financial results. The document is relatively short (2005 characters) and focuses on a specific accounting event rather than presenting a full financial report. It does not contain comprehensive financial statements or detailed financial analysis typical of an Annual Report (10-K) or Interim Report (IR). Instead, it is a regulatory announcement about a specific accounting provision. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2023-04-20 Chinese
金宇生物技术股份有限公司控股股东及实际控制人行为规范管理办法（2023年4月修订）
Governance Information Classification · 95% confidence The document is a detailed set of behavioral norms and governance rules for controlling shareholders and actual controllers of a company, focusing on their responsibilities, restrictions, and disclosure obligations. It references company law, securities law, and stock exchange regulations, and is structured as a governance or compliance guideline document. It does not contain financial statements, audit opinions, earnings data, or meeting results. It is not a report of financial performance or a regulatory filing announcing a report. The content aligns with governance practices and internal rules regarding shareholder conduct and company control. Therefore, the document best fits the category of Governance Information (CGR).
2023-04-20 Chinese
金宇生物技术股份有限公司2022年年度报告摘要
Annual Report Classification · 100% confidence The document is titled as the 2022 annual report summary of 金宇生物技术股份有限公司 (Jinyu Bio-Technology Co., Ltd.). It contains detailed company information, business overview, industry context, product descriptions, management and operational details, and comprehensive financial data including multi-year accounting data and quarterly breakdowns. The document also includes shareholder information and important notes about the company's performance and risks. The presence of extensive financial data, company operations, and strategic information indicates this is a full annual report rather than a brief announcement or a presentation. The document length (8045 characters) and content depth confirm it is the actual annual report, not just a publication announcement or summary. Therefore, the appropriate classification is Annual Report (10-K). FY 2022
2023-04-20 Chinese
金宇生物技术股份有限公司监事会关于会计政策变更的说明
Board/Management Information Classification · 95% confidence The document is a statement from the Supervisory Board regarding a change in accounting policies, referencing a specific accounting standard issued by the Ministry of Finance of China effective from January 1, 2022. It details the board meeting dates and the approval of the accounting policy change, emphasizing that it does not materially affect financial results and does not require shareholder approval. The document is short (529 characters) and focuses on governance and accounting policy changes rather than presenting full financial statements or audit results. It is not an annual report, audit report, or financial statement. It is not a regulatory filing or certification letter either. The content aligns best with Board/Management Information (MANG) as it concerns internal governance decisions about accounting policies approved by the board and supervisory board.
2023-04-20 Chinese
金宇生物技术股份有限公司2023年一季度报告
Interim / Quarterly Report Classification · 100% confidence The document is titled '2023 年第一季度报告' which translates to '2023 First Quarter Report'. It contains detailed financial data including balance sheets, profit and loss statements, cash flow statements, and notes on financial performance for the first quarter of 2023. The document explicitly states it is a quarterly report and includes unaudited financial statements for the period ending March 31, 2023. The length of the document (over 11,000 characters) and the presence of substantive financial data confirm it is a full interim financial report rather than a brief announcement or certification. Therefore, this document fits the definition of an Interim / Quarterly Report (IR). Q1 2023
2023-04-20 Chinese
金宇生物技术股份有限公司2022年度独立董事述职报告
Board/Management Information Classification · 95% confidence The document is titled as an "Independent Directors' Report" for the year 2022 of a company, detailing the independent directors' duties, attendance, opinions, and activities throughout the year. It includes information on board meetings, committee meetings, independent opinions on company matters, and compliance with laws and regulations. The content focuses on governance, board activities, and independent directors' oversight rather than financial results or audit opinions. It is not an annual report (10-K), audit report (AR), or earnings release (ER). It is a detailed report on board/management information specifically about independent directors' duties and activities. Therefore, the document fits best under Board/Management Information (MANG). The document length is sufficient and contains substantive content, not just an announcement or certification, so it is not RPA or RNS.
2023-04-20 Chinese

Browse filings by year

28 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.